

# Charly Gaul

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6875143/publications.pdf>

Version: 2024-02-01

65  
papers

2,300  
citations

279798

23  
h-index

214800

47  
g-index

96  
all docs

96  
docs citations

96  
times ranked

1533  
citing authors

#	ARTICLE	IF	CITATIONS
1	The beneficial effect of positive treatment expectations on pharmacological migraine prophylaxis. <i>Pain</i> , 2022, 163, e319-e327.	4.2	9
2	Aspirin, paracetamol (acetaminophen) and caffeine for the treatment of acute migraine attacks: A systemic review and meta-analysis of randomized placebo-controlled trials. <i>European Journal of Neurology</i> , 2022, 29, 350-357.	3.3	12
3	Assessing attack-related fear in headache disorders: Structure and psychometric properties of the Fear of Attacks in Migraine Inventory. <i>Headache</i> , 2022, 62, 294-305.	3.9	2
4	Long-term open-label safety study of galcanezumab in patients with episodic or chronic cluster headache. <i>Cephalalgia</i> , 2022, 42, 1225-1235.	3.9	5
5	Safety and efficacy of prednisone versus placebo in short-term prevention of episodic cluster headache: a multicentre, double-blind, randomised controlled trial. <i>Lancet Neurology</i> , The, 2021, 20, 29-37.	10.2	38
6	Real-life use of onabotulinumtoxinA for symptom relief in patients with chronic migraine: Repose study German population. <i>Toxicon</i> , 2021, 190, S41-S42.	1.6	0
7	Pain localization in cluster headache patients: Onset, peak, and radiation. <i>Acta Neurologica Scandinavica</i> , 2021, 143, 441-449.	2.1	2
8	Status of clinical research in neurology in Germany: A national survey. <i>European Journal of Neurology</i> , 2021, 28, 1446-1452.	3.3	2
9	Effectiveness of medication in cluster headache. <i>BMC Neurology</i> , 2021, 21, 174.	1.8	3
10	Impact of a 12-week open-label placebo treatment on headache days in episodic and chronic migraine: a study protocol for a parallel-group, multicentre, randomised controlled trial. <i>BMJ Open</i> , 2021, 11, e045969.	1.9	2
11	Real-life use of onabotulinumtoxinA reduces healthcare resource utilization in individuals with chronic migraine: the REPOSE study. <i>Journal of Headache and Pain</i> , 2021, 22, 50.	6.0	10
12	Impact of Galcanezumab on Total Pain Burden: A Post Hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study in Patients with Episodic Cluster Headache. <i>Journal of Pain Research</i> , 2021, Volume 14, 2059-2070.	2.0	2
13	The Mitochondrial Biomarkers FGF-21 and GDF-15 in Patients with Episodic and Chronic Migraine. <i>Cells</i> , 2021, 10, 2471.	4.1	5
14	Burden of Migraine in Patients With Preventive Treatment Failure Attending European Headache Specialist Centers: Real-World Evidence From the BECOME Study. <i>Pain and Therapy</i> , 2021, 10, 1691-1708.	3.2	15
15	Real-world evidence data on the monoclonal antibody erenumab in migraine prevention: perspectives of treating physicians in Germany. <i>Journal of Headache and Pain</i> , 2021, 22, 133.	6.0	16
16	Results of a web-based questionnaire: A gender-based study of migraine with and without aura and possible differences in pain perception and drug effectiveness. <i>Cephalalgia Reports</i> , 2021, 4, 251581632110622.	0.7	0
17	Die Erfassung von Triggerempfindlichkeit und -vermeidung bei primären Kopfschmerzen: Entwicklung und psychometrische Erprobung einer deutschen Version des Headache Triggers Sensitivity and Avoidance Questionnaire (HTSAQ-G). <i>Verhaltenstherapie</i> , 2020, 30, 234-245.	0.4	7
18	The relation between emotion regulation and migraine: A cross-cultural study on the moderating effect of culture. <i>Cephalalgia</i> , 2020, 40, 384-392.	3.9	5

#	ARTICLE	IF	CITATIONS
19	Types of Triggers in Migraine – Factor Structure of the Headache Triggers Sensitivity and Avoidance Questionnaire and Development of a New Short Form (HTSAQ). <i>Headache</i> , 2020, 60, 1920-1929.	3.9	8
20	Treatment Outcomes in Patients Treated With Galcanezumab vs Placebo: Post Hoc Analyses From a Phase 3 Randomized Study in Patients With Episodic Cluster Headache. <i>Headache</i> , 2020, 60, 2254-2264.	3.9	7
21	Use of outpatient medical care by headache patients in Germany: a population-based cross-sectional study. <i>Journal of Headache and Pain</i> , 2020, 21, 49.	6.0	9
22	Determination of psychosocial factors in cluster headache – construction and psychometric properties of the Cluster Headache Scales (CHS). <i>Cephalalgia</i> , 2020, 40, 1240-1249.	3.9	11
23	Triptan efficacy does not predict onabotulinumtoxinA efficacy but improves with onabotulinumtoxinA response in chronic migraine patients. <i>Scientific Reports</i> , 2020, 10, 11382.	3.3	6
24	Do doctors treat themselves differently than their patients? Study on the self-treatment of migraine among German neurologists and pain specialists. <i>Cephalalgia</i> , 2020, 40, 788-796.	3.9	4
25	Prevention of migraine with monoclonal antibodies against CGRP or the CGRP receptor. <i>Neurological Research and Practice</i> , 2020, 2, 11.	2.0	35
26	Peripheral nerve stimulation registry for intractable migraine headache (RELIEF): a real-life perspective on the utility of occipital nerve stimulation for chronic migraine. <i>Acta Neurochirurgica</i> , 2020, 162, 3201-3211.	1.7	13
27	Schmerzerkrankungen. , 2020, , 21-65.		0
28	Non-invasive vagus nerve stimulation (nVNS) for the preventive treatment of episodic migraine: The multicentre, double-blind, randomised, sham-controlled PREMIUM trial. <i>Cephalalgia</i> , 2019, 39, 1475-1487.	3.9	69
29	Differential efficacy of non-invasive vagus nerve stimulation for the acute treatment of episodic and chronic cluster headache: A meta-analysis. <i>Cephalalgia</i> , 2019, 39, 967-977.	3.9	35
30	Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine. <i>Brain</i> , 2019, 142, 1894-1904.	7.6	191
31	An open-label prospective study of the real-life use of onabotulinumtoxinA for the treatment of chronic migraine: the REPOSE study. <i>Journal of Headache and Pain</i> , 2019, 20, 26.	6.0	61
32	An Integrative Cognitive Behavioral Therapy Program for Adults With Migraine: A Feasibility Study. <i>Headache</i> , 2019, 59, 741-755.	3.9	15
33	More Attacks and Analgesic Use in Old Age: Self-Reported Headache Across the Lifespan in a German Sample. <i>Frontiers in Neurology</i> , 2019, 10, 1000.	2.4	16
34	Distribution of migraine attacks over the days of the week: Preliminary results from a web-based questionnaire. <i>Acta Neurologica Scandinavica</i> , 2019, 139, 340-345.	2.1	9
35	Topical Ambroxol 20% for the Treatment of Classical Trigeminal Neuralgia - A New Option? Initial Clinical Case Observations. <i>Headache</i> , 2019, 59, 418-429.	3.9	14
36	Treatment of migraine attacks and prevention of migraine: Guidelines by the German Migraine and Headache Society and the German Society of Neurology. <i>Clinical and Translational Neuroscience</i> , 2019, 3, 2514183X1882337.	0.9	41

#	ARTICLE	IF	CITATIONS
37	Non-invasive vagus nerve stimulation for the acute treatment of episodic and chronic cluster headache: A randomized, double-blind, sham-controlled ACT2 study. <i>Cephalalgia</i> , 2018, 38, 959-969.	3.9	153
38	Prevalence of Headache in Patients With Mitochondrial Disease: A Cross-sectional Study. <i>Headache</i> , 2018, 58, 45-52.	3.9	39
39	Changes in medication cost observed in chronic cluster headache patients treated with sphenopalatine ganglion (SPG) stimulation: Analysis based on 1-year data from the Pathway R-1 Registry. <i>Cephalalgia</i> , 2018, 38, 1455-1462.	3.9	10
40	Chronic Headache Due to Overuse of Analgesics and Anti-Migraine Agents. <i>Deutsches A&amp;#x0308;rzteblatt International</i> , 2018, 115, 365-370.	0.9	28
41	Design and implementation of a platform for the citizen science project migraine radar. <i>IT - Information Technology</i> , 2018, 60, 11-19.	0.9	1
42	Dose Can Help to Achieve Effective Pain Relief for Acute Mild to Moderate Pain with Over-the-Counter Paracetamol. <i>Open Pain Journal</i> , 2018, 11, 12-20.	0.4	5
43	Efficacy and safety of a single occipital nerve blockade in episodic and chronic cluster headache: A prospective observational study. <i>Cephalalgia</i> , 2017, 37, 873-880.	3.9	38
44	Long-term effectiveness of sphenopalatine ganglion stimulation for cluster headache. <i>Cephalalgia</i> , 2017, 37, 423-434.	3.9	110
45	Effects of non-invasive vagus nerve stimulation on attack frequency over time and expanded response rates in patients with chronic cluster headache: a post hoc analysis of the randomised, controlled PREVA study. <i>Journal of Headache and Pain</i> , 2017, 18, 22.	6.0	29
46	Persistent idiopathic facial pain. <i>Cephalalgia</i> , 2017, 37, 680-691.	3.9	87
47	No Pattern Alteration in Single Nocturnal Melatonin Secretion in Patients With Hypnic Headache: A Case-control Study. <i>Headache</i> , 2017, 57, 648-653.	3.9	14
48	Kopf- und Gesichtsschmerzen. , 2017, , 63-93.		0
49	Real-life use of onabotulinumtoxinA for symptom relief in patients with chronic migraine: REPOSE study methodology and baseline data. <i>Journal of Headache and Pain</i> , 2017, 18, 93.	6.0	20
50	Kopfschmerzerkrankungen. , 2017, , 789-798.		0
51	Non-invasive vagus nerve stimulation for PREvention and Acute treatment of chronic cluster headache (PREVA): A randomised controlled study. <i>Cephalalgia</i> , 2016, 36, 534-546.	3.9	219
52	Markers of endothelial function in migraine patients: Results from a bi-center prospective study. <i>Cephalalgia</i> , 2015, 35, 877-885.	3.9	6
53	Subclinical cerebellar dysfunction in patients with migraine: Evidence from eyeblink conditioning. <i>Cephalalgia</i> , 2014, 34, 904-913.	3.9	17
54	Stimulation of the sphenopalatine ganglion (SPG) for cluster headache treatment. Pathway CH-1: A randomized, sham-controlled study. <i>Cephalalgia</i> , 2013, 33, 816-830.	3.9	308

#	ARTICLE	IF	CITATIONS
55	Clinical outcome of a headache-specific multidisciplinary treatment program and adherence to treatment recommendations in a tertiary headache center: an observational study. <i>Journal of Headache and Pain</i> , 2011, 12, 475-483.	6.0	125
56	Team players against headache: multidisciplinary treatment of primary headaches and medication overuse headache. <i>Journal of Headache and Pain</i> , 2011, 12, 511-519.	6.0	73
57	Evaluating integrated headache care: a one-year follow-up observational study in patients treated at the Essen headache centre. <i>BMC Neurology</i> , 2011, 11, 124.	1.8	44
58	Attitudes towards complementary and alternative medicine in chronic pain syndromes: a questionnaire-based comparison between primary headache and low back pain. <i>BMC Complementary and Alternative Medicine</i> , 2011, 11, 89.	3.7	35
59	Impairment in episodic and chronic cluster headache. <i>Cephalalgia</i> , 2011, 31, 671-682.	3.9	98
60	Treatment costs and indirect costs of cluster headache: A health economics analysis. <i>Cephalalgia</i> , 2011, 31, 1664-1672.	3.9	74
61	Prevention of medication overuse in patients with migraine. <i>Pain</i> , 2010, 151, 404-413.	4.2	63
62	Efficacy of Behavioural Therapy for the Prophylaxis of Migraine in Adults: A Randomised Controlled Trial. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
63	Efficacy and Tolerability of Lasmiditan, an Oral 5-HT <sub>1F</sub> Receptor Agonist, for the Acute Treatment of Migraine: A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
64	Migräne: Prophylaxe und Therapie. <i>Deutsches Ärzteblatt International</i> , 0, , .	0.9	0
65	Migräneprophylaxe: Neue Antikörper – wann und wie einsetzen?. , 0, , .		1